Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
REVENUES:
Grant revenue	$ 3,572	$ 1,666
Royalties from product sales and license fees	392	389
Subscription and advertisement revenues	691	1,395
Sale of research products and services	333	8
Total revenues	4,988	3,458	[1]
Cost of sales	(302)	(168)
Gross profit	4,686	3,290
OPERATING EXPENSES:
Research and development	(20,955)	(24,024)
Acquired in-process research and development	(800)
General and administrative	(24,726)	(19,922)
Total operating expenses	(46,481)	(43,946)
Gain on sale of assets		1,754
Loss from operations	(41,795)	(38,902)
OTHER INCOME/(EXPENSES):
Interest income (expense), net	711	(692)
Gain on sale of equity method investment in Ascendance	3,215
Unrealized gain on marketable equity securities (Note 2)	1,158
Loss on extinguishment of related party convertible debt		(2,799)
Other income/(expense), net	(1,315)	1,449
Total other income (expenses), net	(5,335)	15,613
LOSS BEFORE INCOME TAXES	(47,130)	(23,289)
Income tax benefit	346
NET LOSS	(46,784)	(23,289)
Net loss attributable to noncontrolling interest	794	3,313
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	$ (45,990)	$ (19,976)
NET LOSS PER COMMON SHARE:
BASIC AND DILUTED	$ (0.36)	$ (0.17)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC AND DILUTED	126,903,000	114,476,000
AgeX Therapeutics, Inc. [Member]
OTHER INCOME/(EXPENSES):
Gain on sale of shares and deconsolidation	$ 78,511
Loss on equity method investment at fair value	(4,181)
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain on sale of shares and deconsolidation		71,697
Loss on equity method investment at fair value	(47,985)	(2,935)
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Loss on equity method investment at fair value	$ (35,449)	$ (51,107)

[1] Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.